Join collection
Hello, welcome to our official website!
2018亚洲旅游产业年会将于9月在上海召开
2019-01-12

  -中外行业大咖云集,共谋新文旅时代发展之道

  

  上海2018年8月2日电 /美通社/ -- 2018年9月14日,由中国**财经媒体《21世纪经济报道》,联合国内**旅游学府南开大学旅游与服务学院主办的“2018亚洲旅游产业年会”将在上海盛大举行。

  

  本届年会将以“文旅融合·亚洲机遇”为主题,聚焦产业发展和机遇的更深层次议题,关注文旅融合战略下亚洲及全球旅游产业合作发展的新方向、新机遇。  


2017亚洲旅游产业年会

  

  文旅融合加速产业升级,亚洲旅游进入新时代

  

  亚洲旅游产业发展到今天,尤其是随着中国经济结构向消费时代的全面转型、国家“一带一路”倡议推进和自由贸易政策的深化,已成为世界旅游市场发展的主导力量之一。作为聚集新兴发展国家*多的区域,亚洲服务业升级转型必将促进旅游产业的进一步国际化,为旅游产业带来全新的发展机遇。

  

  2018年,伴随国家体制改革向纵深发展,中国正在进入文化塑造与旅游体验相融合的新文旅时代,大型非旅资本正加速进军文旅产业,跨行业投资态势更趋明显。

  

  继成功打造两届亚洲旅游产业年会之后,作为商业报道***,《21世纪经济报道》将携手国内旅游专业顶尖学府南开大学旅游与服务学院,并在南方财经全媒体集团、现代旅游业发展协同创新中心等指导单位的大力支持下,再度推出2018亚洲旅游产业年会。

  

  本届年会包括“拥抱文旅融合的亚洲机遇”主论坛、旅游产业投资与创新高峰论坛、21世纪住宿业高峰论坛,以及2018旅游及住宿业资源推介、对接会等环节。会议将凝聚产业、资本、智库和政府间的多方共识和力量,共同探索各方在投资环境营造、旅游产业规划设计、旅游业态的培育打造、旅游市场的营销策划等合作领域的创新模式,为推进文化与旅游融合发展、促进亚洲经济共同繁荣做出积极贡献。

  

  中外行业大咖云集,共谋新文旅时代发展之道

  

  本届论坛主议题为“拥抱文旅融合的亚洲机遇”。在消费端,2017年中国旅游业对 GDP 的综合贡献为9.13万亿元,占 GDP 总量的11.04%;与此同时,全国规模以上文化及相关产业2017年实现营业收入9.2万亿元,比上年增长10.8%。两个超过9万亿、同样两位数的增长率,不仅证明文旅产业已经融入到我国千家万户的日常生活之中,而且预示着现在文化旅游产业正处于快速布局阶段和大发展的前夜,2018年**数据也证明了这一点,2017年全年中国旅游直接投资超过1.5万亿元,同比增长16%。其中全国已有144支旅游产业投资基金,总规模超过8000亿元。

  

  中国旅游研究院按季度开展的中国城镇和农村居民出游意愿调查数据显示,今年三季度居民总体旅游意愿高达86.4%。现代旅游业发展协同创新中心主任、国家旅游局中国旅游智库秘书长、南开大学教授石培华指出,中国入境旅游80%以上还是亚洲的区域市场,相互交融性更强,同时也是竞争性**的市场。他认为,旅游要想实现共赢,还是要在产业的深度合作上下文章,从大众的观光旅游和专项旅游,发展到融合健康、快乐、文化体验、教育的旅游业态。如何把握住这历史性机遇正是本届年会的聚焦所在。

  

  “掘金文化旅游大时代”是本届年会的另一个主要议题。2018年文旅产业一个鲜明的特点就是在万亿投资中,民间资本投资已经占比达到六成以上,文旅产业已形成民营、国有企业和政府投资共同参与的多元主体投资格局;在这样一个背景下,文旅产业与金融产业的结合已成为大势所趋。2018年一个值得关注的现象是,大型非旅资本正加速进军旅游业,跨行业投资态势更趋明显。比如在重庆近郊江津县,一个覆盖三个乡镇占地近20平方公里总投资超过百亿的乡村振兴加全域旅游项目正在悄然推进,投资者却是此前并未涉足文旅行业的鲁能集团。

  

  实际上,作为一年一度的盛会,2018亚洲旅游产业年会设置了近三十个主旨演讲和圆桌论坛话题,内容包括文化与旅游融合的中国样本、新文旅的投资逻辑、当旅游有了大 IP:文创产业发展机遇、赋能下的旅游项目投资运营之道及爆款IP酒店背后的商业模式探索等。

  

  而作为国内第一家全媒体财经集团所属21世纪经济报道,也充分发挥了媒体平台连接各方资源的优势,2018亚洲旅游产业年会将邀请来自文化和旅游部、联合国世界旅游组织、欧盟旅游委员会、澳大利亚、加拿大、韩国、香港、澳门等旅游局或者大使馆等官员;海南、西安、洛阳等省市地方政府代表;同时还将邀请华侨城集团、复星集团、默林集团、IDG、红杉资本、万达影视、华谊兄弟、长隆集团、华强方特、万豪国际集团、洲际酒店集团、开元酒店集团、携程等近百位行业**参加。

  

  同期活动精彩纷呈,资源对接会、行业颁奖同期举行

  

  论坛当天下午还特设“2018旅游及住宿业资源推介会”,主办方秉持“求真、务实、**”的原则,旨在搭建产业与资本对接的平台,帮助优秀的旅游开发项目、旅游创业项目寻找投资方,为具备资金实力和投资意向的企业及机构挖掘具有投资价值的旅游项目,从而助推旅游业的产融结合,为产业可持续发展贡献力量。


2017亚洲旅游“红珊瑚”奖颁奖典礼

  

  作为亚洲旅游产业年会系列活动之一,组委会还发起举办2018(第十五届)中国酒店“金枕头”奖评选和“亚洲旅游‘红珊瑚’奖”评选活动。“金枕头”奖评选将以大数据评价体系为主要依据,聆听酒店消费者真实声音,甄选**市场口碑和影响力的酒店集团、酒店品牌和单体酒店,发现中国酒店业转型升级中的榜样力量。“红珊瑚”奖评选通过大数据调研、互动投票以及专家评审的方式,对亚洲各旅游目的地、旅游项目、旅游服务商、旅游人物等产业链各方进行客观评价,旨在为大众提供更多旅游消费指引的同时,也帮助旅游产业经营者和管理者了解产业的状况和市场表现,推动亚洲旅游产业的健康发展。2018(第十五届)中国酒店“金枕头”奖和亚洲旅游“红珊瑚”奖的颁奖典礼将于年会当晚隆重举行。


暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Major Chinese biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (Hanmori Pharmaceutical Group Co., Ltd., Hanso Pharmaceutical) and AI ) Atomwise, Inc., a leader in the field, announced the collaboration. The purpose of the collaboration is to design and discover potential drug candidates for a total of 11 private target proteins in multiple therapeutic areas.Atomwise and Hansoh Pharma scientific teams work closely together in each program. The combination of complementary expertise and technology has the potential to dramatically increase success rates and shorten schedules in drug discovery and clinical development.Dr. Aifeng Lyu, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of Hansoh Pharma, said: “Atomwise is the best partner for Hansoh Pharma to use AI technology to innovate and create diverse small molecule pipelines in oncology and other therapeutic areas. I am very impressed with the team and I believe that working together will provide a special opportunity to develop first-in-class and best-in-class therapeutics. "Dr. Abraham Heifets, CEO of Atomwise, said: “It is a great pleasure for us to partner with Chinese biopharmaceutical giant Hansoh Pharma. Hansoh Pharma shares our strong commitment to innovation and our mission to influence patient health globally.”Atomwise's world-class AI platform for structure-based drug design leads the way in finding hit compounds, selecting lead compounds from hit compounds, and optimizing lead compounds. Hansoh Pharma will contribute in its capacity in biological assays and medicinal chemistry, and will lead the subsequent preclinical and clinical development.Subject to the terms of the collaboration, Atomwise will receive revenue based on private technology fees, option exercise fees, royalties, and sublicenses and sales of assets created under the collaboration. Based on historical average sales of small molecule drugs, the overall potential value of this transaction for Atomwise may exceed the potential value of a hit drug if all projects succeed. Hansoh Pharma receives development and commercialization rights in all fields and regions.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

Akari Therapeutics, Plc, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP).“BP, a severe blistering skin condition with no approved treatments, is an exciting therapeutic target for our lead drug candidate, nomacopan. It is also a disease of increasing prevalence due to an aging population and improving diagnosis,” said Clive Richardson, Chief Executive Officer of Akari Therapeutics. “Orphan drug designation for nomacopan is a major step forward for the program, positioning nomacopan for eligibility for an additional seven years of marketing exclusivity in BP if nomacopan is approved by the FDA. This news is in addition to the recent orphan drug designation received for our HSCT-TMA program.”The Company plans to release new safety and efficacy data from an ongoing Phase II trial with nomacopan in patients with BP at an oral presentation by Dr. Christian Sadik at the 28th European Academy of Dermatology and Venereology (EADV) Congress on October 10, 2019. In August, the Company announced new data demonstrating the synergistic benefits of nomacopan’s dual C5 and LTB4 inhibitory activity in pemphigoid disease, generated by Dr. Christian Sadik’s group at University of Lubeck, Germany, and published in the August 2019 edition of JCI Insight [link].Orphan drug designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies Akari for various benefits, including seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and a waiver of certain administrative fees.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

China's leading biopharmaceutical company Hansoh Pharmaceutical Group Company Limited (" Hansen Pharmaceutical ") and drug discovery artificial intelligence (AI) Atomwise, Inc. (" Atomwise ") , a leader in the field, announced a collaborative design and discovery of potential drug candidates for up to 11 unexposed target proteins in a variety of therapeutic areas.Atomwise and Hansen Pharmaceutical's scientific team will work closely together in these projects. The combination of complementary expertise and technology is expected to significantly increase success and reduce timelines for drug discovery and clinical development.Dr. Lu Aifeng, President of Jiangsu Hansoh Pharmaceutical Group Co., Ltd., said: Hansen Pharmaceutical is committed to using AI technology to innovate and develop diverse small molecules in the field of cancer and other therapeutics. Atomwise is the right partner for Hansen Pharmaceuticals. We are very impressed with Atomwise's AI platform, capabilities and team. We believe that the two companies will have an excellent opportunity to develop similar and best-in-class therapeutic drugs. ."Dr. Abraham Heifets, CEO of Atomwise, said: "We are very excited to work with Hansen Pharmaceutical, China's leading biopharmaceutical company. Hansen Pharmaceuticals and we all have strong commitment to innovation and a common mission to influence the health of patients worldwide. ."The world-class AI platform for Atomwise structured drug design will guide efforts in hit discovery, accidental discovery to hit-to-lead selection, and optimization of lead compounds. Hansen Pharmaceuticals is committed to biological testing and pharmaceutical chemistry, as well as leading subsequent preclinical and clinical development activities.Under the terms of the partnership, Atomwise will receive undisclosed technology royalties, optional royalties, royalties, and subcontracting authorizations or revenue generated from the sale of the derivative assets. Based on the historical average turnover of small molecule drugs, the potential total value of all successful projects with Atomwise's transaction may exceed potential selling drugs. Hanson Pharmaceuticals will receive development and commercialization rights in all fields and geographies.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases announces the signing of a collaboration agreement with Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences), an innovation-driven biopharmaceutical company to evaluate the combination therapy of I-Mab's TJD5, a proprietary innovative CD73 antibody with Junshi Biosciences' Toripalimab (Trade name: Tuoyi), a recombinant humanized anti-PD-1 monoclonal antibody in patients with cancers in China.Dr. Jingwu Zang, Founder and Chairman of I-Mab, commented, "TJD5 is an innovative CD73 antibody with best-in-class potential that has entered into Phase I trial in the US. We are very pleased to collaborate with Junshi to explore the clinical synergies with Toripalimab which is an innovative drug with distinctive treatment advantages. We are looking forward to bringing more clinical benefits to patients across various cancer types."Dr. Ning Li, CEO of Junshi Biosciences, commented, "As an anti multi-tumor drug, toripalimab has shown good safety and efficacy in clinical trials with mono and combination therapy. We believe, through the cooperation with I-Mab, we could continue to explore the combination potential of toripalimab and innovative drugs to improve the outcomes of immune-oncology therapy, lightening hope for more patients.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

TUESDAY, SEPTEMBER 10, 2019ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a license agreement with Bayer AG for the  GlymaxX® Technology. Under the terms of the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications.ProBioGen’s proven antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX® will be applied during cell line development.“We are glad to add Bayer to our list of licensees”, says ProBioGen’s Chief Executive Officer Dr. Wieland Wolf. “The GlymaxX® technology is clinically proven and is a very flexible technology which is liked by all cell lines.”About ProBioGen AGProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic antibodies and glycoproteins. Combining both state-of-the-art development services, based on ProBioGen’s CHO.RiGHT™ expression and manufacturing platform, together with intelligent product-specific technologies yields biologics with optimized properties.Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).ProBioGen was founded 1994, is privately owned, and located in Berlin, Germany.About GlymaxX®The GlymaxX® technology, developed by ProBioGen, prevents the cellular synthesis of the sugar “fucose” and hence, in antibody-producing cells, its addition to the N-linked carbohydrate part of the antibody. The absence of fucose is known to greatly enhance ADCC. The GlymaxX® technology is based on the stable introduction of a gene for an enzyme which blocks the producer cells’ fucose biosynthesis pathway. As a unique feature, differentiating it from other approaches, GlymaxX® can be applied to both novel or already existing antibody producer cell lines, and entire antibody expression and discovery platforms, without negatively affecting their productivity or other product characteristics.Furthermore, a single GlymaxX® cell line can be flexibly used to produce differently fucosylated products, depending on the upstream process: In fucose-free medium the antibody is quantitatively afucosylated. The same GlymaxX® cell line grown in fucose-containing medium however, uses the provided fucose and produces fully fucosylated antibody. Thus, a GlymaxX® cell line can by employed to produce different products: For instance ADCC-enhanced GlymaxX® antibodies or wildtype-like, fully fucosylated mAbs, for a parallel Antibody-Drug-Conjugate (ADC) project.Finally, GlymaxX® has been used by biosimilar-developing companies to adjust a specific content of fucose in order to match the originators glycoprofile. Overall, GlymaxX® is simple, rapid, potent, and universally applicable to different CHO hosts and all other eukaryotic cell species.ProBioGen offers its GlymaxX® technology royalty-free and non-exclusively as a service or as an individual license.2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/404716/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://www.zenseegroup.com/forms/view/22113/

About Us
Contact Us
Zensee_Daystar online